An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Concert Pharmaceuticals (NASDAQ: CNCE) announced its participation in a virtual fireside chat at The Jefferies London Healthcare Conference. This on-demand chat will be available starting at 8:00 a.m. GMT on November 18, 2021. Investors can access the webcast through the Investors section of Concert's website. A replay will be available for two weeks post-presentation. Concert Pharmaceuticals focuses on developing small molecule drugs using its DCE Platform, with its lead candidate in late-stage development for treating alopecia areata.
Positive
None.
Negative
None.
LEXINGTON, Mass.--(BUSINESS WIRE)--
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a virtual fireside chat at The Jefferies London Healthcare Conference. The on-demand fireside chat will be available beginning at 8:00 a.m. GMT on November 18, 2021.
A webcast of the Jefferies fireside chat may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the webcast will be available on Concert’s website for two weeks following the presentation.
About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.
When will Concert Pharmaceuticals participate in The Jefferies London Healthcare Conference?
Concert Pharmaceuticals will participate in The Jefferies London Healthcare Conference on November 18, 2021, with the chat available from 8:00 a.m. GMT.
How can I access the webcast of Concert Pharmaceuticals' fireside chat?
The webcast of Concert Pharmaceuticals' fireside chat can be accessed in the Investors section of their website.
What is Concert Pharmaceuticals' lead product candidate?
Concert Pharmaceuticals' lead product candidate is in late-stage development for the treatment of alopecia areata.
What is the significance of the DCE Platform for Concert Pharmaceuticals?
The DCE Platform allows Concert Pharmaceuticals to enhance the pharmacokinetic and metabolic properties of small molecule drugs.
How long will the replay of the webcast be available?
The replay of the webcast will be available on Concert Pharmaceuticals' website for two weeks following the presentation.
